NasdaqGS - Nasdaq Real Time Price USD
Lyell Immunopharma, Inc. (LYEL)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 4:59 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
54.0000
130.0000
84,683.0000
10,650.0000
7,756.0000
--
Operating Expense
225,704.0000
247,138.0000
271,741.0000
225,426.0000
219,693.0000
--
Operating Income
-225,650.0000
-247,008.0000
-187,058.0000
-214,776.0000
-211,937.0000
--
Net Non Operating Interest Income Expense
26,875.0000
23,453.0000
7,053.0000
1,165.0000
5,939.0000
--
Other Income Expense
-11,484.0000
-11,077.0000
-3,113.0000
-36,608.0000
1,526.0000
--
Pretax Income
-210,259.0000
-234,632.0000
-183,118.0000
-250,219.0000
-204,472.0000
--
Net Income Common Stockholders
-210,259.0000
-234,632.0000
-183,118.0000
-250,219.0000
-208,054.0000
--
Diluted NI Available to Com Stockholders
-210,259.0000
-234,632.0000
-183,118.0000
-250,219.0000
-208,054.0000
--
Basic EPS
-0.83
-0.93
-0.74
-1.84
-0.98
--
Diluted EPS
-0.83
-0.93
-0.74
-1.84
-0.98
--
Basic Average Shares
253,446.0000
250,983.0000
247,080.0000
135,918.0000
211,746.0000
--
Diluted Average Shares
253,446.0000
250,983.0000
247,080.0000
135,918.0000
211,746.0000
--
Total Operating Income as Reported
-225,650.0000
-247,008.0000
-187,058.0000
-214,776.0000
-211,937.0000
--
Total Expenses
225,704.0000
247,138.0000
271,741.0000
225,426.0000
219,693.0000
--
Net Income from Continuing & Discontinued Operation
-210,259.0000
-234,632.0000
-183,118.0000
-250,219.0000
-204,472.0000
--
Normalized Income
-197,258.0000
-221,709.0000
-178,118.0000
-213,772.0000
-204,472.0000
--
Interest Income
26,875.0000
23,453.0000
7,053.0000
1,165.0000
5,939.0000
--
Net Interest Income
26,875.0000
23,453.0000
7,053.0000
1,165.0000
5,939.0000
--
EBIT
-225,650.0000
-247,008.0000
-187,058.0000
-214,776.0000
-211,937.0000
--
EBITDA
-205,564.0000
-226,758.0000
-169,038.0000
-201,152.0000
-207,643.0000
--
Reconciled Depreciation
20,086.0000
20,250.0000
18,020.0000
13,624.0000
4,294.0000
--
Net Income from Continuing Operation Net Minority Interest
-210,259.0000
-234,632.0000
-183,118.0000
-250,219.0000
-204,472.0000
--
Total Unusual Items Excluding Goodwill
-13,001.0000
-12,923.0000
-5,000.0000
-36,447.0000
--
--
Total Unusual Items
-13,001.0000
-12,923.0000
-5,000.0000
-36,447.0000
--
--
Normalized EBITDA
-192,563.0000
-213,835.0000
-164,038.0000
-164,705.0000
-207,643.0000
--
12/31/2019 - 6/17/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IKNA Ikena Oncology, Inc.
1.7100
0.00%
GLUE Monte Rosa Therapeutics, Inc.
5.52
+0.55%
RLYB Rallybio Corporation
1.1200
+2.75%
IPSC Century Therapeutics, Inc.
1.6000
+1.91%
ERAS Erasca, Inc.
2.9100
+3.93%
PEPG PepGen Inc.
8.94
+0.79%
ALXO ALX Oncology Holdings Inc.
1.4800
-1.99%
GBIO Generation Bio Co.
2.2600
-2.16%
NGNE Neurogene Inc.
54.40
+2.80%
XLO Xilio Therapeutics, Inc.
0.7790
-2.38%